Arix Bioscience plc Competitors

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $485 billion of assets under management as of June 30, 2026, Carlyle’s purpose is to connect people, ideas, and capital to fuel growth for companies and performance for investors. Carlyle employs more than 2,500 people in 28 offices across four continents. Nothing herein constitutes an offer to sell, or a solicitation of an offer to buy, any security or product of Carlyle or any Carlyle-managed fund. Additional notices & disclaimers can be found here: https://www.carlyle.com/notices-and-disclaimers

LGT Capital Partners is a leading global specialist in alternative investing with over USD 120 billion in assets under management and more than 750 institutional clients in 50 countries. An international team of over 950 professionals is responsible for managing a wide range of investment programs focusing on private markets, multi-alternatives and diversifying strategies, complemented by sustainable and impact strategies. Headquartered in Pfaeffikon (SZ), Switzerland, the firm has offices in San Francisco, New York, Dublin, London, Paris, The Hague, Luxembourg, Frankfurt am Main, Vaduz, Dubai, Beijing, Hong Kong, Tokyo, Singapore and Sydney.

Sartorius is a leading international partner of biopharma research and manufacturing. We help our customers simplify progress from drug discovery to manufacturing so that more people can have access to better medicine. And simplifying progress starts with our employees who move things forward by realizing ambitious ideas and growing alongside with the company. Our product portfolio covers two customer groups: With innovative laboratory instruments and consumables, Sartorius focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. Our broad bioprocess product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with more than 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2025, Sartorius generated sales revenue of around 3.5 billion euros. Currently, more than 14,000 employees from 110+ nations are working for customers around the globe. Join our team, partner or collaborate with us.